Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase

Structure

Volumn 10, Issue 7, 2002, Pages 1013-1023

  Powers, Rachel A ^a   Morandi, Federica ^a   Shoichet, Brian K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antibiotic resistance; Molecular docking; Novel inhibitor discovery; Structure based drug design; X ray structure

Indexed keywords

3 [(4 CHLOROANILINO)SULFONYL]THIOPHENE 2 CARBOXYLIC ACID; AMPICILLIN; BETA LACTAMASE INHIBITOR; UNCLASSIFIED DRUG; 3 ((4 CHLOROANILINO)SULFONYL)THIOPHENE 2 CARBOXYLIC ACID; 3-((4-CHLOROANILINO)SULFONYL)THIOPHENE-2-CARBOXYLIC ACID; AMPC BETA LACTAMASES; AMPC BETA-LACTAMASES; ANILINE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; ENZYME INHIBITOR; THIOPHENE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; ESCHERICHIA COLI; MICROBIOLOGICAL EXAMINATION; STRUCTURE ACTIVITY RELATION;

AMPICILLIN; ANILINE COMPOUNDS; ANTI-INFECTIVE AGENTS; BETA-LACTAMASES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ENZYME INHIBITORS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THIOPHENES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS;

EID: 0036076470     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(02)00799-2     Document Type: Article

References (41)

1. The crisis in antibiotic resistance
2. Inactivation of antibiotics and the dissemination of resistance genes
3. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase
4. Phosphonate monoester inhibitors of class A beta-lactamases
5. The inhibition of class C beta-lactamases by boronic acids
6. Structure-activity relationships in the inhibition of serine beta-lactamases by phosphonic acid derivatives
7. Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase
8. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-lactamase
9. Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases
10. Structure-based approach for binding site identification on AmpC beta-lactamase
11. Flexible ligand docking using conformational ensembles
12. Ligand solvation in molecular docking
13. A geometric approach to macromolecule-ligand interactions
14. Orientational sampling and rigid-body minimization in molecular docking
15. Evidence for an oxyanion hole in serine beta-lactamases and DD-peptidases
16. Procheck: A program to check the stereochemical quality of protein structures
17. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase
18. Refined crystal structure of beta-lactamase from Citrobacter freundii indicates a mechanism for beta-lactam hydrolysis
19. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A beta-lactamases from the antibiotic-resistant bacteria
20. Crystal structures of substrate and inhibitor complexes with AmpC beta-lactamase: Possible implications for substrate-assisted catalysis
21. Crystal structures of the Bacillus licheniformis BS3 class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin
22. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: Mechanistic interpretation of a beta-lactamase transition-state analog
23. Inhibition of beta-lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies
24. Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 Å resolution
25. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: Implications for resistance mutations and inhibitor design
26. Structural milestones in the reaction pathway of an amide hydrolase: Substrate, acyl, and product complexes of cephalothin with AmpC beta-lactamase
27. The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: Heat-labile enterotoxin, a multivalent test case
28. The particle concept: Placing discrete water molecules during protein-ligand docking predictions
29. Protein structure prediction methods for drug design
30. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
31. The MIDAS display system
32. Matching chemistry and shape in molecular docking
33. Automated docking with grid-based energy evaluation
34. Calculation of electrostatic potentials in an enzyme active site
35. New class IV charge model for extracting accurate partial charges from wave functions
36. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction-mechanisms, and different types and mechanisms of inhibition
37. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening
38. Processing of X-ray diffraction data collected in oscillation mode
39. Crystallography and NMR system: A new software suite for macromolecular structure determination
40. Improved methods for building protein models in electron-density maps and the location of errors in these models
41. Setor: Hardware-lighted three-dimensional solid model representations of macromolecules